Critics Question World Health Organization's Stance on E-cigarettes

Regulations by 2FIRSTS.ai
Apr.10.2024
Critics Question World Health Organization's Stance on E-cigarettes
World Health Organization's statement on e-cigarette-induced seizures sparks controversy on social media, prompting fact-checking and debate.

According to a report by the Daily Mail, the World Health Organization recently made a statement on the social platform "X", claiming that e-cigarettes can cause seizures within a few hours, which has sparked criticism from various parties. The global health organization's statement on "X" was fact-checked by internet users, and the social platform later released a community statement.

 

Critics Question World Health Organization's Stance on E-cigarettes
Translate to English: WHO post | Image source: X

 

The announcement stated: "The basis of this post is research that has not been peer-reviewed and the evidence is uncertain. The basis of this statement is approximately 120 uncertain events that have occurred since 2019."

 

Dr. Charles Gardner, a developmental neurobiologist in Brooklyn, tweeted, "Please provide peer-reviewed evidence to support the claim that e-cigarettes 'typically' trigger seizures within 24 hours. If you cannot do this, please delete your tweet. Note: I have reviewed the literature and have not found any studies showing that e-cigarettes increase the risk of seizures.

 

In addition, some users have referred to the World Health Organization as clowns and liars, claiming that they are spreading propaganda. Steve Rolles, senior policy analyst at the Transform Drug Policy Foundation, also said, "I am convinced this is nonsense. Why is the World Health Organization's stance on e-cigarettes so peculiarly out of line?"

 

Critics Question World Health Organization's Stance on E-cigarettes
Supplementary statement of the WHO post | Image source: X

 

In a community announcement on "X," a link to an editorial on e-cigarettes and epilepsy was included. The editorial, published in the Journal of Adolescent Health, discusses a 2019 study analyzing 122 cases of seizure and other neurological symptoms in individuals who reported using e-cigarettes in the past 24 hours. Due to its potential to trigger seizures, researchers suggest that participants may be at risk for nicotine-induced epilepsy and symptoms.

 

However, the editorial pointed out that the details of the study "raise questions about causality, which must be considered when assessing the actual health risks of nicotine e-cigarettes for adolescents." It also noted, "A major question is why inhaling nicotine from e-cigarettes can trigger seizures, while inhaling nicotine from traditional tobacco does not.

 

The authors point out that a person would need to inhale a large dose of nicotine to trigger a seizure, but e-cigarette devices contain much lower levels of nicotine compared to traditional cigarettes. Additionally, the toxic effects of high doses of nicotine are expected to appear within minutes of inhalation and dissipate within a few hours. The authors state, "Seizures do not seem likely to occur if there are no other systemic toxic effects present.

 

In the United States, the use of e-cigarettes has reached record levels, with over 17 million adults and 2 million children addicted to these devices. An editorial pointed out a flaw in a 2019 study, stating that the analysis of reported seizures was based on self-reporting and not always clear. Descriptions varied, with some individuals reporting severe seizures while others detailed tremors or seizure-like activity. In most cases, these events were not evaluated by medical professionals. The editorial's author noted that nicotine could potentially cause anxiety attacks and unconscious muscle contractions, leading some individuals to misinterpret these symptoms as seizures, even though they are not.

 

Despite traditional cigarette smoking rates decreasing each year, the number of people using e-cigarettes is continuously increasing, especially among middle and high school students. An analysis from the Centers for Disease Control and Prevention (CDC) in 2023 found that 2.1 million children, or nearly 8% of the student population, are using these devices, with 47% of children who have tried e-cigarettes still currently using them.

 

E-cigarettes typically come in attractive flavors such as cotton candy and caramel custard, and their packaging designs appeal to younger users. Data shows that approximately 90% of young people report having used products with fruit or candy flavors.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa plans to publish its first vapor products directory on November 16, 2026, after which products not listed will be prohibited from sale or offer for sale in the state. The Department of Revenue expects to begin penalty enforcement on December 17, following an initial 21-business-day period focused on compliance education. Under House File 2677, retailers, distributors and wholesalers selling unlisted products face civil penalties of $300 per product per day, while manufacturers face $1,000 per product per day. Eligibility extends to FDA-authorized products and certain products meeting historical marketing and pending PMTA requirements. The directory program resumed after a federal appeals court vacated a preliminary injunction in July 2026.
Regulations
Nov.05
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
NEXTECH launched its NEXE Pro circumferential-heating tobacco stick globally at InterTabac 2026, as the company expands from product innovation into broader heated tobacco solutions. Amid intensifying competition across global HTP markets, NEXTECH is strengthening its R&D, manufacturing and pre-launch support capabilities to serve different types of business customers.
Industry Insight
Sep.15